down arrow

NovaBay Pharmaceuticals, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US66987P3001
USD
1.09
0.03 (2.83%)

Dec 04

ASE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.011.09

52 Week

0.464.44
Valuation
Technical
Day's Volume

CASH

47.06 k

Shareholding (Mar 2025)

FII

0.41%

Held by 3 FIIs

DII

98.85%

Held by 1 DIIs

Promoter

0.00%

How big is NovaBay Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, NovaBay Pharmaceuticals, Inc. has a market capitalization of 3.60 million and reported net sales of 7.15 million with a net profit of -7.44 million over the latest four quarters. Shareholder's funds are at -0.13 million, and total assets amount to 45.91 million.

As of Jun 18, NovaBay Pharmaceuticals, Inc. has a market capitalization of 3.60 million, classifying it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 7.15 million, while the sum of net profit for the same period is -7.44 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at -0.13 million, and total assets amount to 45.91 million.

Read More

What does NovaBay Pharmaceuticals, Inc. do?

22-Jun-2025

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing eye care products, particularly the prescription Avenova for eyelid and lash hygiene. It has a market cap of $3.60 million and reported a net profit loss of $3 million as of March 2025.

Overview: <BR>NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company that develops products for the eye care market, focusing on prescription Avenova for eyelid and lash hygiene, and operates within the Pharmaceuticals & Biotechnology industry with a micro-cap market capitalization.<BR><BR>Financial Snapshot: <BR>Market cap: USD 3.60 Million (Micro Cap) <BR>Net Profit: -3 Million (Quarterly Results - Mar 2025)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.32 <BR>Return on Equity: -109.52% <BR>Price to Book: 0.58<BR><BR>Contact Details: <BR>Address: 2000 Powell St Ste 1150, EMERYVILLE CA 94608-1804 <BR>Tel: 1 510 8998800 <BR>Fax: 1 510 2250371 <BR>Website: http://novabay.com/

Read More

Who are in the management team of NovaBay Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of NovaBay Pharmaceuticals, Inc. includes Mr. Paul Freiman (Independent Chairman), Mr. Justin Hall (President and CEO), and directors Mr. Xinzhou Li, Mr. Mijia Wu, Ms. Swan Sit, and Dr. Yenyou Zheng.

As of March 2022, the management team of NovaBay Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Mr. Paul Freiman, who serves as the Independent Chairman of the Board.<BR>- Mr. Justin Hall, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. Xinzhou Li, who is a Director.<BR>- Mr. Mijia Wu, who is also a Director.<BR>- Ms. Swan Sit, who serves as an Independent Director.<BR>- Dr. Yenyou Zheng, who is another Independent Director.<BR><BR>In summary, the management team consists of a mix of independent directors and executive leadership, with Mr. Justin Hall at the helm as CEO.

Read More

Is NovaBay Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of August 20, 2025, NovaBay Pharmaceuticals, Inc. shows a bullish technical trend with strong MACD and moving average indicators, despite a bearish monthly RSI, and has significantly outperformed the S&P 500 with a 211.45% return over the past month.

As of 20 August 2025, the technical trend for NovaBay Pharmaceuticals, Inc. has changed from mildly bearish to bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages also indicate a bullish stance. However, the monthly RSI shows a bearish signal, and the weekly RSI has no signal. Bollinger Bands are bullish on a monthly basis and mildly bullish weekly. The KST is bullish weekly and mildly bullish monthly, while the Dow Theory reflects a mildly bullish stance in both time frames. The OBV shows a bullish trend monthly but no trend weekly.<BR><BR>In terms of performance, the stock has returned 211.45% over the past month, significantly outperforming the S&P 500's 2.33% return, and has a year-to-date return of 222.80% compared to the S&P 500's 12.22%. Overall, the current technical stance is bullish, driven primarily by the bullish indicators in MACD, moving averages, and Bollinger Bands.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 16 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.17

stock-summary
Return on Equity

-171.87%

stock-summary
Price to Book

3.70

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-74.17%
0%
-74.17%
6 Months
82.58%
0%
82.58%
1 Year
91.26%
0%
91.26%
2 Years
-89.26%
0%
-89.26%
3 Years
-98.49%
0%
-98.49%
4 Years
-99.8%
0%
-99.8%
5 Years
-99.86%
0%
-99.86%

NovaBay Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is NovaBay Pharmaceuticals, Inc. technically bullish or bearish?

As of 20 August 2025, the technical trend for NovaBay Pharmaceuticals, Inc. has changed from mildly bearish to bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages also indicate a bullish stance. However, the monthly RSI shows a bearish signal, and the weekly RSI has no signal. Bollinger Bands are bullish on a monthly basis and mildly bullish weekly. The KST is bullish weekly and mildly bullish monthly, while the Dow Theory reflects a mildly bullish stance in both time frames. The OBV shows a bullish trend monthly but no trend weekly. In terms of performance, the stock has returned 211.45% over the past month, significantly outperforming the S&P 500's 2.33% return, and has a year-to-date return of 222.80% compared to the S&P 500's 12.22%. Overall, the current technical stance is bullish, driven primarily by the bullish indicators in MACD, moving averages,...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-12.38%
EBIT Growth (5y)
-1.22%
EBIT to Interest (avg)
-6.70
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.32
Sales to Capital Employed (avg)
4.81
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
8.85%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.55
EV to EBIT
0.78
EV to EBITDA
0.80
EV to Capital Employed
2.43
EV to Sales
-0.66
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
313.51%
ROE (Latest)
-109.52%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 3 Schemes (0.74%)

Foreign Institutions

Held by 3 Foreign Institutions (0.41%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 39.39% vs -153.85% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.90",
          "val2": "-2.60",
          "chgp": "26.92%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.60",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.00",
          "val2": "-3.30",
          "chgp": "39.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -6.67% vs -27.08% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -18.03% vs 62.58% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "9.80",
          "val2": "10.50",
          "chgp": "-6.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.60",
          "val2": "-3.70",
          "chgp": "-24.32%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.90",
          "val2": "1.70",
          "chgp": "-47.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-7.20",
          "val2": "-6.10",
          "chgp": "-18.03%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-508.50%",
          "val2": "-392.30%",
          "chgp": "-11.62%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-1.90
-2.60
26.92%
Interest
0.10
0.00
Exceptional Items
0.00
-0.60
100.00%
Consolidate Net Profit
-2.00
-3.30
39.39%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs -100.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 39.39% vs -153.85% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
9.80
10.50
-6.67%
Operating Profit (PBDIT) excl Other Income
-4.60
-3.70
-24.32%
Interest
0.90
1.70
-47.06%
Exceptional Items
0.10
0.00
Consolidate Net Profit
-7.20
-6.10
-18.03%
Operating Profit Margin (Excl OI)
-508.50%
-392.30%
-11.62%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -6.67% vs -27.08% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -18.03% vs 62.58% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About NovaBay Pharmaceuticals, Inc. stock-summary
stock-summary
NovaBay Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. Its Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging. It develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. Its Aganocide compounds, led by auriclosene (NVC-422), are synthetic molecules with activity against bacteria, viruses and fungi. The Company's dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. Its wound care business includes the business of NeutroPhase product.
Company Coordinates stock-summary
Company Details
2000 Powell St Ste 1150 , EMERYVILLE CA : 94608-1804
stock-summary
Tel: 1 510 8998800
stock-summary
http://novabay.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."